Physician profile
Edward R Arrowsmith
NPI 1780632687
$12,442.61
in general payments reported to CMS, 2019-2025
52 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $475 · 2021: $7,695 · 2022: $782 · 2023: $760 · 2024: $875 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.03 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $8,148.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $436.56 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $258.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $256.51 | 2019-2025 | Opdivo, Pomalyst |
| Amgen INC. | $237.69 | 2019-2023 | Blincyto, Kyprolis |
| Astellas Pharma US INC | $190.28 | 2019-2025 | Vyloy |
| Merck Sharp & Dohme LLC | $176.89 | 2019-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $175.09 | 2024-2025 | |
| Abbvie INC. | $174.54 | 2019-2025 | Venclexta |
| Daiichi Sankyo INC. | $153.97 | 2024-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $139.15 | 2019-2025 | Libtayo |
| Lilly USA, LLC | $131.99 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Pfizer INC. | $124.39 | 2019-2024 | |
| Aveo Pharmaceuticals, INC. | $121.40 | 2022-2025 | |
| Heron Therapeutics, INC. | $116.00 | 2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $110.76 | 2025 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $109.22 | 2019-2024 | Alunbrig, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $108.53 | 2023-2024 | |
| Janssen Biotech, INC. | $107.41 | 2023-2024 | Imbruvica, Darzalex, Talvey |
| Exelixis INC. | $96.86 | 2022-2023 | Cabometyx |
| Incyte Corporation | $95.19 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Celgene Corporation | $94.58 | 2019-2025 | Reblozyl, Breyanzi |
| Gilead Sciences, INC. | $91.25 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $90.85 | 2019-2024 | Xermelo, Zoladex |
| Eisai INC. | $81.97 | 2023-2025 | |
| Adc Therapeutics America, INC. | $72.29 | 2023-2024 | |
| Array Biopharma INC | $56.22 | 2019-2025 | Lorbrena, Braftovi, Ibrance |
| G1 Therapeutics, INC. | $48.42 | 2022-2023 | Cosela |
| Genmab U.S., INC. | $39.30 | 2024 | Epkinly |
| Genzyme Corporation | $35.89 | 2025 | |
| Morphosys, US INC. | $35.60 | 2023-2024 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $34.90 | 2023-2024 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $30.12 | 2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $28.37 | 2024 | |
| Emd Serono, INC. | $27.04 | 2024 | |
| Pharmaessentia USA Corporation | $26.38 | 2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $25.62 | 2025 | Qinlock, Romvimza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.05 | 2019 | |
| Pharmacosmos Therapeutics INC. | $22.04 | 2025 | Monoferric |
| Taiho Oncology, INC. | $21.43 | 2025 | |
| Glaxosmithkline, LLC. | $21.19 | 2024 | Zejula, Jemperli |
| Mirati Therapeutics, INC. | $20.90 | 2023 | Krazati |
| Sobi, INC | $19.43 | 2025 | |
| Cti Biopharma Corp. | $15.58 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $11.69 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Arrowsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.